Moderna Stock Surges 100% After Successful Melanoma Vaccine Trial
A personalized mRNA cancer treatment developed with Merck reduces skin cancer recurrence, validating the platform beyond COVID-19.
Moderna shares skyrocketed on August 19, 2026, following the announcement of positive clinical trial results for a personalized mRNA melanoma vaccine. The breakthrough marks a pivotal moment for the company as it seeks to diversify its portfolio beyond infectious diseases.
In collaboration with Merck, Moderna reported positive Phase 3 trial results for the INTerpath-001 study. The personalized vaccine, used in combination with the immunotherapy drug pembrolizumab (Keytruda), successfully reduced the risk of recurrence in patients with melanoma. The market reacted sharply to the news, with Moderna's stock price jumping over 100% in a single session. Some reports indicated the surge reached as high as 145%, pushing the share price to $154.48.
The Pivot to Oncology
Founded in 2010, Moderna gained global prominence through the rapid development of its COVID-19 vaccines. However, the company has spent the last several years pivoting its mRNA platform toward oncology and other infectious diseases. By March 2026, Moderna had expanded its pipeline to include 25 mRNA development candidates in various stages of clinical studies. This shift represents a strategic effort to move from a pandemic-response company to a broad-based biotechnology leader.
Validation of mRNA Technology
The success of the melanoma vaccine is a critical validation of mRNA technology's application in personalized medicine. Unlike traditional vaccines that target a general pathogen, this treatment is tailored to the specific genetic mutations of an individual patient's tumor. This capability potentially opens a massive new market in personalized cancer treatment, shifting the paradigm from general chemotherapy toward precision immunotherapy.
Future Outlook
Investors will now watch for the regulatory filing process and the timeline for potential FDA approval. While the Phase 3 results provide a strong foundation, the scalability of personalized manufacturing remains a key operational hurdle for Moderna and Merck. Furthermore, the industry will be monitoring whether this success triggers a broader wave of mRNA-based cancer trials across other tumor types, which could further redefine the oncology landscape.